DNA X, Inc. Insider Trading Activity

DNA X, Inc. Acting CEO and director Michael C. Mulica reported an equity compensation grant.

Rhea-AI Filing Summary

DNA X, Inc. Acting CEO and director Michael C. Mulica reported an equity compensation grant. On February 9, 2026, he was awarded 50,000 restricted stock units of common stock at a price of $0.00 per unit as a service-based grant.

The units vest in equal monthly installments over one year, contingent on his continued service. Following this grant, he beneficially owns 54,071 securities, consisting of 4,071 shares of common stock and 50,000 unvested restricted stock units. These figures reflect a 1-for-18 reverse stock split that took effect on October 27, 2025.

Insider Trade Summary

Grant/Award: 50,000 shares

Grant/Award 1 txn

Insider MULICA MICHAEL C

Role Acting CEO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	50,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 54,071 shares (Direct)

Footnotes (3)

1. F1. Represents the grant of restricted stock units that vest in equal monthly installments over a one-year period following the date of the grant, subject to the Reporting Person's continued service to the Issuer. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock.
2. F2. Consists of (i) 4,071 shares of common stock and (ii) 50,000 unvested restricted stock units.
3. F3. The number of securities reported herein reflects the effects of a 1-for-18 reverse stock split effected by the Issuer on October 27, 2025, which was exempt from reporting pursuant to Rule 16a-9.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did DNA X (SONM) report for Michael C. Mulica?

DNA X reported that Acting CEO and director Michael C. Mulica received a grant of 50,000 restricted stock units on February 9, 2026. The grant was priced at $0.00 per unit and represents equity compensation rather than an open-market stock purchase.

How do Michael C. Mulica’s restricted stock units in DNA X (SONM) vest?

The 50,000 restricted stock units granted to Michael C. Mulica vest in equal monthly installments over one year. Vesting is conditioned on his continued service to DNA X, and each unit represents the right to receive one share of common stock.

How many DNA X (SONM) securities does Michael C. Mulica beneficially own after this grant?

After the reported grant, Michael C. Mulica beneficially owns 54,071 securities of DNA X. This consists of 4,071 shares of common stock and 50,000 unvested restricted stock units tied to future vesting over a one-year period.

Was the DNA X (SONM) insider transaction a purchase or a compensation grant?

The Form 4 shows a compensation grant, not a market purchase. Michael C. Mulica received 50,000 restricted stock units at $0.00 per unit, indicating an equity award provided by DNA X as part of his role, rather than stock bought on the open market.

How did DNA X (SONM)’s reverse stock split affect Michael C. Mulica’s reported holdings?

Michael C. Mulica’s reported 54,071 securities already reflect DNA X’s 1-for-18 reverse stock split effective October 27, 2025. The filing notes that the reverse split was exempt from separate reporting, so all share figures in the Form 4 are post-split amounts.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/10/2026 - 08:53 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MULICA MICHAEL C

(Last) (First) (Middle)

C/O DNA X, INC.

4445 EASTGATE MALL, SUITE 200

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
DNA X, Inc. [ SONM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Acting CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/09/2026		A		50,000(1)	A	$0.00	54,071(2)(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the grant of restricted stock units that vest in equal monthly installments over a one-year period following the date of the grant, subject to the Reporting Person's continued service to the Issuer. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock.

2. Consists of (i) 4,071 shares of common stock and (ii) 50,000 unvested restricted stock units.

3. The number of securities reported herein reflects the effects of a 1-for-18 reverse stock split effected by the Issuer on October 27, 2025, which was exempt from reporting pursuant to Rule 16a-9.

	/s/ Clay Crolius, by power of attorney	02/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.